Solovic, Ivan and Sester, Martina and Gómez Reino, Juan J. and Rieder, Hans L. and Ehlers, S. and Milburn, Heather J. and Kampmann, Beate and Hellmich, Bernhard and Groves, R. and Schreiber, Stefan and Wallis, Robert S. and Sotgiu, Giovanni and Schölvinck, Elisabeth H. and Goletti, Delia and Zellweger, Jean-Pierre and Diel, R. and Carmona, Loreto and Bartalesi, Filippo and Ravn, P. and Bossink, Aik and Duarte, R. and Erkens, Connie and Clark, J. and Migliori, Giovanni Battista and Lange, Christoph (2010) The Risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal, Vol. 36 (5), p. 1185-1206. eISSN 1399-3003. Article.
Full text not available from this repository.
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB).
I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore
Repository Staff Only: item control page